G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 102 filers reported holding G1 THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 1.08 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28 | -95.8% | 19,366 | -92.7% | 0.00% | -97.0% |
| Q2 2023 | $662 | -99.5% | 266,017 | +2309.1% | 0.07% | +266.7% |
| Q3 2022 | $138,000 | -86.3% | 11,042 | -94.6% | 0.02% | -88.1% |
| Q2 2022 | $1,006,000 | +143.6% | 203,545 | +469.5% | 0.15% | +118.8% |
| Q3 2020 | $413,000 | +47.5% | 35,742 | +40.6% | 0.07% | -1.4% |
| Q1 2020 | $280,000 | – | 25,428 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 1,423,794 | $34,541,000 | 9.18% |
| Burrage Capital Management LLC | 373,876 | $9,070,000 | 6.35% |
| Birchview Capital, LP | 40,000 | $970,000 | 0.59% |
| 361 CAPITAL LLC | 47,325 | $1,148,000 | 0.54% |
| Rhenman & Partners Asset Management AB | 190,000 | $4,609,000 | 0.50% |
| CHI Advisors LLC | 44,000 | $1,067,000 | 0.42% |
| Bellevue Group AG | 721,925 | $17,514,000 | 0.25% |
| Candriam S.C.A. | 870,423 | $21,117,000 | 0.22% |
| Virtus ETF Advisers LLC | 18,991 | $461,000 | 0.22% |
| HHLR ADVISORS, LTD. | 949,431 | $23,033,000 | 0.21% |